Montelukast Normon (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Normon, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is indicated for maintenance therapy of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in appropriate patients. GNH USA supplies Montelukast Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic airway inflammation and allergic symptoms. - Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Dizziness: brief episodes. - Fatigue: mild tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Hematologic abnormalities: neutropenia or eosinophilia. - Severe bronchospasm: unexpected worsening of breathing. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Assess asthma control: ensure baseline therapy is optimized. - Monitor neuropsychiatric symptoms: watch for mood changes or depression. - Use with caution in hepatic impairment: adjust therapy if liver disease is present. - Avoid in patients with known hypersensitivity to Montelukast or excipients. - Review concomitant medications: consider potential drug interactions. - Store at ambient temperature: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to the interaction severity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase Montelukast exposure. - Phenobarbital or other enzyme inducers: may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may heighten neuropsychiatric risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential for increased bronchospasm. - Rifampin: may lower Montelukast plasma concentrations.